Despite extensive research and improvements in understanding colorectal cancer (CRC), its
metastatic form continues to pose a substantial challenge, primarily owing to limited …

Therapeutic options for metastatic colorectal cancer (mCRC) are very limited, and the
prognosis using combination therapy with a chemotherapeutic drug and a targeted agent …

Clinical trials have identified ARID1A mutations as enriched among patients who respond
favorably to immune checkpoint blockade (ICB) in several solid tumor types independent of …

The BEACON CRC study demonstrated that encorafenib (Enco)+ cetuximab
(Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux+ …

CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …

Colorectal cancer is caused by a sequence of somatic genomic alterations affecting driver
genes in core cancer pathways. Here, to understand the functional and prognostic impact of …

Cancer-associated fibroblasts (CAF) and nerves, components of the tumor
microenvironment, have each been shown to directly promote gastrointestinal cancers …

Breast cancer (BC) is a leading cause of cancer-related death worldwide. The diverse
nature and heterogeneous biology of BC pose challenges for survival prediction, as patients …

Identification of potential bacterial players in colorectal tumorigenesis has been a focus of
intense research. Herein, we find that Clostridium symbiosum (C. symbiosum) is selectively …

Association with hypomethylating agents is a promising strategy to improve the efficacy of
immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation …